Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

NCT05122026 is registered in ClinicalTrials.gov with The Aurum Institute NPC as lead sponsor.

NCT NCT05122026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Lead sponsor
The Aurum Institute NPC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 17, 2024
Completion date
December 31, 2025
Enrollment
252 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv seropositivity, pregnancy, tuberculosis infection